Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 2/20 | 0.39 |
| ▸ | ANPEP | P15144 | 2/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.39 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
| ▸ | NPY4R | P50391 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.38 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.38 |
| ▸ | CHRND | Q07001 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14453772 | 0.94 | F2 (0.46) | F2NTSR2NTSR1OPRD1ANPEP | |
| SCHEMBL14453771 | 0.94 | F2 (0.45) | F2NTSR2NTSR1OPRD1ANPEP | |
| SCHEMBL14453784 | 0.92 | NPY1R (0.45) | F2NPY1RANPEPLNPEPIL23R | |
| SCHEMBL14453781 | 0.89 | F2 (0.41) | F2NTSR2NTSR1OPRD1NPY1R | |
| SCHEMBL14453773 | 0.89 | F2 (0.41) | F2NTSR2NTSR1OPRD1NPY1R | |
| SCHEMBL14453778 | 0.89 | F2 (0.41) | F2NTSR2NTSR1OPRD1NPY1R | |
| SCHEMBL13160647 | 0.83 | FYN (0.42) | ANPEPLNPEP | |
| SCHEMBL13160651 | 0.77 | F2 (0.36) | F2NTSR2NTSR1NPBWR1OPRD1 | |
| SCHEMBL13160649 | 0.76 | SRC (0.45) | — | |
| SCHEMBL14472337 | 0.70 | HDAC1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173437-A1 | BISUBSTRATE INHIBITORS OF PROTEIN TYROSINE KINASES AS THERAPEUTIC AGENTS | RHODE ISLAND BOARD OF EDUCATION, STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS | 2007-07-26 | — | — | US | disclosed |
| US-20070173437-A1 | BISUBSTRATE INHIBITORS OF PROTEIN TYROSINE KINASES AS THERAPEUTIC AGENTS | RHODE ISLAND BOARD OF EDUCATION, STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173437-A1 | BISUBSTRATE INHIBITORS OF PROTEIN TYROSINE KINASES AS THERAPEUTIC AGENTS | DSTYK, SRC, PTK2B | F2 3158/4885NTSR2 1500/4885NTSR1 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.